Abstract: According to one embodiment, a magnetic disk device comprises magnetic disks, heads, and a controller. The controller does not allocate logical addresses to sectors of a first area to be specified in such a manner as to correspond to a defect existing in a predetermined recording area, the first area being within the predetermined recording area constituted of a plurality of cylinders adjacent to each other in the magnetic disks, and uniquely allocates logical addresses to sectors of a second area other than the first area. The controller makes allocation of logical addresses to the sectors of the second area different from each other according to the number of defects existing in the predetermined recording area.

Abstract: According to one embodiment, a magnetic disk device comprises magnetic disks, heads, and a controller. The controller does not allocate logical addresses to sectors of a first area to be specified in such a manner as to correspond to a defect existing in a predetermined recording area, the first area being within the predetermined recording area constituted of a plurality of cylinders adjacent to each other in the magnetic disks, and uniquely allocates logical addresses to sectors of a second area other than the first area. The controller makes allocation of logical addresses to the sectors of the second area different from each other according to the number of defects existing in the predetermined recording area.

Abstract: According to one embodiment, a magnetic disk device includes a magnetic disk, a head and a controller. The head writes data to the magnetic disk and reads data from the magnetic disk. The controller once reads the data written to a predetermined recording area according to the number of writes of data to the predetermined recording area of the magnetic disk and rewrites the read data to the predetermined recording area. The controller adjusts an additive value to the number of writes based on the presence or absence of a defect on the recording surface of the magnetic disk.

Abstract: According to one embodiment, a magnetic disk device includes a magnetic disk, a head and a controller. The head writes data to the magnetic disk and reads data from the magnetic disk. The controller once reads the data written to a predetermined recording area according to the number of writes of data to the predetermined recording area of the magnetic disk and rewrites the read data to the predetermined recording area. The controller adjusts an additive value to the number of writes based on the presence or absence of a defect on the recording surface of the magnetic disk.

Abstract: According to one embodiment, there is provided a method for determining whether a defect on a disk in an apparatus includes head is a recess or a protrusion. The method detects a first defect on the disk using a read element provided in the head. The method detects a second defect on the disk using a head disk interference sensor provided in the head. The method further determines whether a third defect is a recessed defect or a protruding defect based on a ratio between a first width of the first defect in a radial direction on the disk and a second width of the second defect in the radial direction of the disk. The third defect is identified based on the first defect and the second defect.

Abstract: According to one embodiment, there is provided a method for determining whether a defect on a disk in an apparatus includes head is a recess or a protrusion. The method detects a first defect on the disk using a read element provided in the head. The method detects a second defect on the disk using a head disk interference sensor provided in the head. The method further determines whether a third defect is a recessed defect or a protruding defect based on a ratio between a first width of the first defect in a radial direction on the disk and a second width of the second defect in the radial direction of the disk. The third defect is identified based on the first defect and the second defect.

Abstract: One aspect of the embodiments is related to a method of controlling a flying height of a head slider. The method includes the steps of measuring a first correlation value between an air pressure and a heating element sensitivity of the head slider, measuring a second correlation value between the air pressure and the flying height of the head slider, calculating a reference heating-element sensitivity at normal air pressure from the first correlation value, measuring a heating element sensitivity of the heating element when the head slider is lifted, calculating the difference between the heating element sensitivity and the reference heating-element sensitivity to calculate an amount of variation in air pressure from the first correlation value, and calculating an amount of variation in the flying height of the head slider from the amount of variation in air pressure and the second correlation value and controlling the heating element.

Abstract: A pharmaceutical product, a functional food or the like has been demanded which can reduce the fatigue in a tired person and enables the tired person to lead a fulfilled life. Disclosed is a fatigue-reducing agent. The fatigue-reducing agent comprises ornithine or a salt thereof and glutathione or a salt thereof as active ingredients.

Abstract: According to one embodiment, a magnetic storage apparatus configured to write data to and read data from a magnetic medium with a head includes a setting module, a write module, a read module, and a quality measurement module. The setting module sets a plurality of sections divided in the track direction of the magnetic medium and a predetermined reference path along the track direction, and also sets at least one offset for each of the sections such that the offset is different between adjacent sections. The offset is the position of the head with respect to the reference path. The write module writes a first data pattern to the offset set by the setting module and writes a second data pattern to the reference path a predetermined number of times. The read module reads the first data pattern written by the write module. The quality measurement module measures the quality of the first data pattern read by the read module.

Abstract: The present invention is directed to a process for producing trans-4-hydroxy-L-proline, which is useful as a raw material for medicines or as an additive to foods. In the process, L-proline is converted into trans-4-hydroxy-L-proline in the presence of an enzyme source which is derived from a microorganism belonging to the genus Dactylosporangium, Amycolatopsis or Streptomyces and which catalyzes the hydroxylation of L-proline into trans-4-hydroxy-L-proline, a divalent iron ion and 2-ketoglutaric acid, in an aqueous medium, and the produced trans-4-hydroxy-L-proline is collected from the aqueous medium. In addition, the present invention is directed to a process for producing trans-4-hydroxy-L-proline, wherein the L-proline biosynthesis activity of the host cell of the transformant is reinforced.

Abstract: One aspect of the embodiments is related to a method of controlling a flying height of a head slider. The method includes the steps of measuring a first correlation value between an air pressure and a heating element sensitivity of the head slider, measuring a second correlation value between the air pressure and the flying height of the head slider, calculating a reference heating-element sensitivity at normal air pressure from the first correlation value, measuring a heating element sensitivity of the heating element when the head slider is lifted, calculating the difference between the heating element sensitivity and the reference heating-element sensitivity to calculate an amount of variation in air pressure from the first correlation value, and calculating an amount of variation in the flying height of the head slider from the amount of variation in air pressure and the second correlation value and controlling the heating element.

Abstract: In accordance with the present invention, there are provided a preventive or of preventing or therapeutic agent for decubitus comprising an N-acylated derivative of hydroxyproline or a salt thereof; the above preventive or therapeutic agent wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight; and the preventive or therapeutic agent for decubitus wherein the N-acylated group of the N-acylated derivative of hydroxyproline is an N-acylated group having 1 to 24 carbon atoms.

Abstract: The present invention is directed to a process for producing trans-4-hydroxy-L-proline, which is useful as a raw material for medicines or as an additive to foods. In the process, L-proline is converted into trans-4-hydroxy-L-proline in the presence of an enzyme source which is derived from a microorganism belonging to the genus Dactylosporangium, Amycolatopsis or Streptomyces and which catalyzes the hydroxylation of L-proline into trans-4-hydroxy-L-proline, a divalent iron ion and 2-ketoglutaric acid, in an aqueous medium, and the produced trans-4-hydroxy-L-proline is collected from the aqueous medium. In addition, the present invention is directed to a process for producing trans-4-hydroxy-L-proline, wherein the L-proline biosynthesis activity of the host cell of the transformant is reinforced.

Abstract: A person, who has symptoms including difficulty in going to sleep, feeling languid after waked up or having a hard time awaking, is desirous of a medicament and a nutritional food that can alleviate the symptoms and improve his or her health. Specifically, one object of the present invention is to provide an orally administered agent, a food and drink, or a food additive which can be used for improving the process of going to sleep and waking. An orally administered agent, a food and drink, or a food additive for improving the process of going to sleep and waking, containing ornithine or a salt thereof as an active ingredient can be provided according to the present invention.

Abstract: An isolated gene encodes for a L-proline-3-hydroxylase having the amino acid sequence of SEQ ID NOS: 1, 2, 15, 16 and 17, or for a protein having enzymatic activity to hydroxylate the 3-position of L-proline and to act on free L-proline in the presence of 2-ketoglutaric acid and divalent iron ions to produce cis-3-hydroxy-L-proline. The gene is inserted into a vector and the resulting recombinant DNA is used to create a transformant. L-proline-3-hydroxylase is produced by culturing the transformant in a medium.

Abstract: The present invention provides a chewable tablet having an improved oral disintegration property, which is easily chewed and capable of containing a large amount of an amino acid depending on need, more specifically, a chewable tablet comprising an amino acid and an oral disintegration promoting agent.

Abstract: In accordance with the present invention, there are provided a preventive or of preventing or therapeutic agent for decubitus comprising an N-acylated derivative of hydroxyproline or a salt thereof; the above preventive or therapeutic agent wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight; and the preventive or therapeutic agent for decubitus wherein the N-acylated group of the N-acylated derivative of hydroxyproline is an N-acylated group having 1 to 24 carbon atoms.

Abstract: An object of the present invention is to provide an amino acid-containing drink and a method for reducing the bitterness of amino acids. The bitterness of an amino acid can be reduced by adding ornithine to the amino acid. Further, an amino acid-containing composition with reduced bitterness can be prepared by having ornithine contained in the composition.

Abstract: An isolated gene encodes for a L-proline-3-hydroxylase having the amino acid sequence of SEQ ID NOS: 1, 2, 15, 16 and 17, or for a protein having enzymatic activity to hydroxylate the 3-position of L-proline and to act on free L-proline in the presence of 2-ketoglutaric acid and divalent iron ions to produce cis-3-hydroxy-L-proline. The gene is inserted into a vector and the resulting recombinant DNA is used to create a transformant. L-proline-3-hydroxylase is produced by culturing the transformant in a medium.

Abstract: An isolated gene encodes for a L-proline-3-hydroxylase having the amino acid sequence of SEQ ID NOS: 1, 2, 15, 16 and 17, or for a protein having enzymatic activity to hydroxylate the 3-position of L-proline and to act on free L-proline in the presence of 2-ketoglutaric acid and divalent iron ions to produce cis-3-hydroxy-L-proline. The gene is inserted into a vector and the resulting recombinant DNA is used to create a transformant. L-proline-3-hydroxylase is produced by culturing the transformant in a medium.